CJC-1295

CJC-1295 is a synthetic 30-amino acid peptide analog of growth hormone-releasing hormone (GHRH), a hypothalamic neuropeptide that stimulates the pituitary gland to release growth hormone (GH). The defining feature of CJC-1295 is the Drug Affinity Complex (DAC) modification — a maleimido-propionic acid (MPA) group that causes the peptide to covalently bind to serum albumin after injection. This albumin binding dramatically extends the peptide's half-life from approximately 7 minutes (for native GHRH) to 6–8 days.

This extended half-life is both the primary innovation and a point of controversy with CJC-1295. While a longer half-life reduces injection frequency and provides sustained GH stimulation, the resulting "bleed" of continuous GH elevation differs from the natural pulsatile GH release pattern. Some researchers and clinicians prefer using CJC-1295 without DAC (which behaves more like modified GHRH with a shorter but extended half-life) to maintain more physiological pulsatility when combined with GH secretagogues like Ipamorelin.

Growth hormone stimulation through GHRH analogs like CJC-1295 is distinct from direct GH injection: it stimulates the body's own pituitary GH production and release, maintaining the natural negative feedback mechanisms that regulate GH levels. This is considered by many researchers to be a safer approach than exogenous GH administration.

CJC-1295 is not FDA-approved and is not approved for human use outside of research contexts. It is commonly used in the performance enhancement and anti-aging research communities.

CJC-1295 works through the following pathway:

• GHRH receptor agonism: CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary, mimicking the action of endogenous GHRH. This triggers intracellular signaling cascades (cAMP/PKA, calcium) that promote synthesis and secretion of growth hormone.
• Albumin binding (DAC): After injection, the DAC modification allows CJC-1295 to covalently bond to the Cys34 residue of circulating albumin, dramatically extending its half-life and creating a depot of active peptide that slowly releases from the albumin-peptide complex.
• IGF-1 stimulation: The GH released in response to CJC-1295 acts on the liver and other tissues to stimulate production of insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic and tissue-building effects.
• Pulsatile vs. continuous stimulation: With DAC, CJC-1295 provides more continuous GH stimulation; without DAC, the half-life is shorter (approximately 30 minutes) and stimulation is more pulse-like. The continuous stimulation from DAC may blunt natural GH pulses through pituitary desensitization over time.
• Preserved feedback regulation: Unlike exogenous GH administration, CJC-1295 preserves the natural negative feedback loop: elevated GH and IGF-1 reduce pituitary sensitivity, limiting excessive GH elevation.

CJC-1295 shares potential benefits with other GHRH-stimulating compounds, derived from its GH/IGF-1 elevating effects:

• Muscle mass increase: Elevated IGF-1 promotes muscle protein synthesis, satellite cell activation, and muscle hypertrophy — the primary driver of interest in performance contexts.
• Fat loss: GH has direct lipolytic effects, mobilizing stored fat for energy, and elevated GH/IGF-1 ratios favor body recomposition toward more lean mass.
• Accelerated recovery: GH and IGF-1 support tissue repair, collagen synthesis, and recovery from training stress or injury.
• Improved sleep quality: GH is primarily secreted during deep sleep, and increasing overall GH secretion may improve sleep quality through feedback relationships with sleep architecture.
• Anti-aging effects: GH and IGF-1 levels decline with age. Partial restoration through GHRH stimulation may slow some aspects of the aging phenotype, including reduced muscle mass, increased visceral fat, and impaired recovery.
• Bone density: GH and IGF-1 support osteoblast activity and bone remodeling, potentially beneficial for age-related bone density loss.

CJC-1295 side effects are largely extensions of elevated GH/IGF-1 activity:

• Water retention: One of the most commonly reported effects; GH promotes sodium and water retention, leading to bloating and temporary weight gain from fluid.
• Injection site reactions: Redness, pain, and swelling at the injection site
• Headache: Particularly in early use, possibly related to fluid changes
• Carpal tunnel-like symptoms: Elevated GH can cause fluid accumulation in the carpal tunnel, causing tingling or numbness in hands — a well-known GH side effect.
• Facial flushing: Reported shortly after injection
• Pituitary desensitization: Continuous GHRH receptor stimulation (particularly with the DAC version) may reduce pituitary responsiveness over time, potentially blunting natural GH pulsatility.
• IGF-1 elevation concerns: High IGF-1 has been associated with increased cancer risk in some epidemiological studies, though causality is contested. People with personal or family cancer histories should exercise caution.
• Insulin resistance: GH is counter-regulatory to insulin; sustained GH elevation may reduce insulin sensitivity.

Clinical development of CJC-1295 with DAC was halted in 2006 following the death of a trial participant (myocardial infarction). The compound was developed by ConjuChem Biotechnologies. While a direct causal link was not conclusively established, this event contributed to the cessation of clinical trials.

Disclaimer: CJC-1295 is not FDA-approved for human use. The following is for educational purposes only.

Common research community protocols:

• CJC-1295 with DAC: 1–2 mg injected subcutaneously once per week (long half-life allows weekly dosing)
• CJC-1295 without DAC (Modified GRF 1-29): 100–300 mcg injected subcutaneously, 1–3 times per day (preferred when combined with Ipamorelin for pulsatile GH release)
• Combination with Ipamorelin: CJC-1295 without DAC (100 mcg) + Ipamorelin (100 mcg) injected together before bed is one of the most commonly described protocols in the research community
• Timing: Best administered when blood glucose is low (fasted state or 2+ hours after meals) as elevated insulin blunts GH release

CJC-1295 has been evaluated in some published human studies:

• Teichman et al. (2006): A Phase II study demonstrated that CJC-1295 with DAC produced dose-dependent, sustained increases in GH and IGF-1 in healthy adults, with mean GH levels elevated 2–10-fold over baseline and IGF-1 elevated 1.5–3-fold, persisting for weeks after a single injection. This confirmed the pharmacological concept of extended GHRH analog activity.
• Animal muscle studies: Rodent and animal studies show muscle mass increases and improved body composition with GHRH analog treatment.
• Comparison to GH therapy: GHRH stimulation maintains natural pulsatility (especially without DAC), potential advantages in preserving feedback regulation, and may have a more favorable side effect profile than direct GH.

Notable limitations include the absence of long-term human safety trials and the lack of research on its use in combination with Ipamorelin (the most common protocol in the research community). The Phase II trial provides pharmacological validation but does not constitute evidence of safety or efficacy for ongoing use in healthy individuals.